A rival's trial failure has challenged the shared scientific hypothesis between Amgen and Novartis.

1 report, 1 independent Updated Sep 13

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Amgen Novartis

Keep exploring

Part of

Amgen and Novartis have developed similar drugs aimed at treating heart conditions. All 2 developments

Within Multiple companies, including Eli Lilly, Amgen, Ionis, and Novartis, are developing advanced experimental drugs for heart disease, including those targeting Lp(a).

The entities involved

Amgen
American multinational biopharmaceutical company
- Laurus Labs is shifting focus from building to filling capacity and may participate in Amgen's supply chain.Fri 11:34
- Reports on market moves involving Nike, Amgen, and Investopedia, amidst the ongoing Iran conflict.Thu 22:11
Novartis
Swiss-American multinational pharmaceutical corporation
- Sean Maenpaa, with experience at Novartis and Celgene, was appointed SVP Business Development at Clovis Oncology.Fri 12:53
- FDA endorsed broader use of a Lilly medicine, and Abogen furnished Novartis with RNA technology.Thu 04:37

Coverage

Newest first; wire copies grouped

Sep 13yahoo.com